People with mild or moderate hemophilia may struggle to get prophylactic treatment because their disease severity classification does not always match their bleeding symptoms. Additionally, racial and ethnic minority groups with hemophilia often face systemic and socioeconomic circumstances that prevent them from accessing optimized care. It is important for healthcare providers to recognize the barriers to appropriate hemophilia treatment and take actionable steps to overcome institutional, social, economic, and other roadblocks so that all patients can benefit from advances in therapy.
In this 30-minute CME Snack video, experts in hemophilia explore new and emerging therapies that can improve outcomes for patients with hemophilia. A case study presentation provides additional clinical perspective and offers ways to provide equitable treatment in underserved patient groups.
At the conclusion of this activity, learners will be able to better:
Supported by an educational grant from Novo Nordisk, Inc.
Hematologists, hematologist/oncologists, physician associates (PAs), nurse practitioners (NPs), nurses and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 0.50 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This application-based activity is approved for 0.50 contact hours ( 0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-044-H01-P).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 07/09/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Ms. Bloomberg reports the following financial relationships:
Advisory Board: Genentech, Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: Bayer; Genentech, Inc.; Novo Nordisk; and Sanofi
Dr. Young reports the following financial relationships:
Advisory Board: BioMarin; Centessa Pharmaceuticals; Genentech, Inc./Roche; HEMA Biologics, LLC/LFB USA; Novo Nordisk; Octapharma USA; Pfizer Inc.; Sanofi Genzyme; Spark; and Takeda Pharmaceuticals U.S.A., Inc.
Consultant: BioMarin; Centessa Pharmaceuticals; CSL Behring; Genentech, Inc./Roche; HEMA Biologics, LLC/LFB USA; Novo Nordisk; Octapharma USA; Pfizer Inc.; Sanofi Genzyme; Spark Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: Sanofi
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Call us at 877.CME.PROS (877.263.7767).
SN-239-071224-68
